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With a substantial impact on morbidity and mortality, the growing “epidemic” of atrial
fibrillation (AF) intersects with a number of conditions, including aging, thromboembolism,
hemorrhage, hypertension and left ventricular dysfunction. Currently, the epidemiology and
natural history of AF govern all aspects of its clinical management. The ongoing global
investigative efforts toward understanding AF are also driven by epidemiologic findings. New
developments, by affecting the natural history of the disease, could eventually alter the nature
of decision making in patients with AF. The crucial issue of rate versus rhythm control awaits
completion of the AF Follow-up Investigation of Rhythm Management trial. The processes
of electrical and structural remodeling that perpetuate AF appear to be reversible. In the era
of functional genomics, the molecular basis of this ubiquitous arrhythmia is in the process of
being defined. Unraveling the molecular genetics of AF might provide new insights into the
structural and electrical phenotypes resulting from genetic mutations and, as such, new
approaches to treatment of this arrhythmia at the ion channel and cellular levels. Thus,
current adverse trends are superimposed on a background of a rapidly developing knowledge
base and potentially exciting new therapeutic options. Consequently, an understanding of the
epidemiology and natural history of AF is crucial to the future allocation of resources and the
utilization of an expanding range of therapies aimed at reducing the impact of this disease on
a changing patient population. (J Am Coll Cardiol 2001;37:371–8) © 2001 by the American
College of Cardiology
INCIDENCE AND PREVALENCE
As we enter the 21st century, atrial fibrillation (AF), an
“old” arrhythmia that was first identified in 1909 (1), has
assumed increasing importance as the global demographic
tide results in a burgeoning population of elderly individu-
als. Indeed, Braunwald, in his Shattuck lecture (2), referred
to the growing “epidemic” of AF. The impact of AF on
mortality and morbidity is substantial, as are the socioeco-
nomic consequences in relationship to hospital admissions,
chronic disease management and disabilities. These adverse
trends, nonetheless, are superimposed on a background of
potentially exciting new therapeutic options. Consequently,
an understanding of the epidemiology and natural history of
AF is crucial to the future allocation of resources and the
utilization of an expanding range of therapies aimed at
reducing the impact of this disease on a changing patient
population (3).
Atrial fibrillation currently affects approximately 2.2 mil-
lion patients in the U.S. (4) and is the most common
rhythm disorder among U.S. patients hospitalized with a
primary diagnosis of an arrhythmia (5). The median age of
patients is 75 years; approximately 70% of patients are
between the ages of 65 and 85 years, and 84% are older than
65 years (4) (Fig. 1). Pooled data from studies of chronic AF
in North America, Britain and Iceland suggest a prevalence
of 0.5% to 1% in the general population (6–9). In two
separate studies restricted to patients older than 60 years,
the prevalence was 5% to 9% after 5 to 15 years of follow-up
(10,11). Thus, the genesis of this epidemic was initially
attributed to alterations in the age-related composition of
the population, with an expanding elderly population ac-
counting for the increasing incidence and prevalence of AF.
However, during the past two decades, additional factors
seem to have influenced the frequency of this disease. The
Framingham study found an increasing prevalence of AF
even after adjusting for age, gender and other comorbidities
(Fig. 2) (12); but underlying explanations are unclear, and
further studies in other populations are needed. From a
recent population-based study in subjects older than 65
years, the prevalence in men (9.1%) was greater than that in
women (4.8%) (13). In the Framingham study, after adjust-
ment for age and other risk factors, AF developed in men at
1.5 times the rate in women. The reason for the greater
susceptibility to AF in men is unexplained (14).
Evidence for underestimation of AF. Significant in-
creases in numbers notwithstanding, there is a strong
likelihood that the incidence and prevalence of AF may be
substantially underestimated. Underdetection due to ab-
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sence of symptoms and undersampling in patients with
paroxysmal AF are significant constraints to the clarification
of the epidemiology of AF. Thirty percent of patients
enrolled in the Cardiovascular Health Study (13) and
approximately 45% of patients in the Stroke Prevention in
Atrial Fibrillation (SPAF-III) study had AF detected inci-
dentally (15) when electrocardiography was performed for
an unrelated reason. In patients with symptomatic par-
oxysmal AF, there is a 12:1 ratio of asymptomatic versus
symptomatic episodes (16).
The bulk of our knowledge of the epidemiology of AF is
based predominantly on white populations. In the Cardio-
vascular Health study, there was a trend toward a lower
incidence of AF during follow-up in blacks, but they made
up only 5% of the total population in that study (17).
DIRECT RELATIONSHIP OF AF TO MORTALITY
Until recently, the status of AF as an independent predictor
of mortality in myocardial infarction, heart failure or stroke
was unclear (18–23). New information from the Framing-
ham study, however, may have put this controversy to rest
(24). Even among low-risk subjects without clinically rele-
vant cardiovascular disease, AF was still associated with an
excess mortality. In subjects age 55 to 94 years from the
original cohort of the Framingham study, the presence of
AF independently increased the risk of death in men (odds
ratio [OR]: 1.5; 95% confidence interval [CI]: 1.2 to 1.8)
and women (OR: 1.9; 95% CI: 1.5 to 2.2). When subjects
who died within 30 days of diagnosis were excluded, the OR
decreased to 1.1 in men but was unchanged in women.
Consequently, the presence of AF limited the advantage
that women have over men in regard to longevity. Mecha-
nisms remain speculative, and, in this study, data were
insufficient to examine the role of anticoagulants or antiar-
rhythmic agents on mortality (24).
INCIDENCE OF STROKE AND HEMORRHAGE
Atrial fibrillation is an independent risk factor for stroke; it is
associated with a four- to five-fold higher risk than in the
unaffected population (9,25–27). Overall, this rhythm disorder
is implicated in approximately 75,000 strokes per year and is
probably the major cause of embolic stroke (28). Patients with
paroxysmal or intermittent AF have an annualized stroke rate
(3.2%) similar to that in patients with chronic or sustained AF
(3.3%) (29). The coexistence of other factors in patients with
AF may compound the risk of stroke. For instance, the risk of
stroke attributable to AF increases with age (28). Thus, older
patients are not only more prone to AF but their risk of stroke
is considerably increased compared with younger patients with
AF. The propensity of the elderly for stroke may be related to
a higher prevalence of comorbid conditions and to the dual
factors of age and chronicity. Both increasing age and chro-
nicity of AF correlate strongly with increased left atrial size
(30).
Do predictors of stroke risk explain mechanisms of
stroke occurrence? Traditional concepts of the pathophys-
iology of stroke and AF implicate stasis and thrombus
formation in a structurally abnormal and dilated atrium or
ventricle (31) (Fig. 3). More recent investigations suggest
that AF may independently confer a hypercoagulable state
(32,33). Considerable interest currently focuses on an ex-
panded paradigm in which AF is not a putative risk factor
for stroke but rather a “marker” for other conditions
predisposing to stroke, including aortic atherosclerosis, ce-
rebrovascular disease and mitral annular calcification (34–
37) (Fig. 3).
Hypertension is a powerful independent predictor of stroke
in patients with nonrheumatic AF (36,37) (Table 1). In a
recent large trial, a history of hypertension was strongly
associated with findings of left atrial stasis and thrombi on
Figure 1. Prevalence of atrial fibrillation in four natural history studies.
CHS 5 Cardiovascular Health Study; W Australia 5 Western Australia.
(From Feinberg et al. [4]; by permission of the American Medical
Association).
Figure 2. Secular trends in the prevalence (percentage) of atrial fibrillation
in subjects 65 to 84 years old in the Framingham study. (Data from Wolf
et al. [13]).
Abbreviations and Acronyms
AF 5 atrial fibrillation
CHF 5 congestive heart failure
LV 5 left ventricle, left ventricular
SOLVD 5 Studies Of Left Ventricular Dysfunction
SPAF 5 Stroke Prevention in Atrial Fibrillation trial
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transesophageal echocardiography (38) and the presence or
absence of complex aortic plaque, which determined high or
moderate risk of thromboembolism, respectively. Perhaps in
some patients the presence of hypertension acts as a marker of
a noncompliant atherosclerotic aorta, which increases the
impedance to left atrial and left ventricular (LV) emptying,
promoting chamber dilatation and stasis, in addition to the
potential for atheroembolic cerebrovascular disease. The strong
association between hypertension and stroke in patients with
nonrheumatic AF needs further clarification. Determination of
the precise relationships among severity of hypertension, extent
of blood pressure control and stroke in patients with AF could
also have important implications for clinical management.
Diabetes emerged as a risk factor for stroke in some studies
(39), but this has not been a consistent observation.
The importance of age as a risk factor. When a group of
344 patients were stratified for stroke risk on the basis of
clinical criteria, 75% of patients younger than 65 years were
at low risk, but approximately 70% of patients older than 65
were at moderate risk and a third were at high risk (40). In
the elderly, the epidemiologic evidence supporting an in-
creased risk of stroke is strongest, but this has to be offset by
the increased risk of bleeding. A recent analysis from the
Stroke Prevention in Atrial Fibrillation (SPAF) trial
showed that high-risk patients are identifiable with the
same clinical criteria in both intermittent and sustained AF
(29).
Benefit of warfarin for stroke prophylaxis. A recent meta-
analysis evaluated the effectiveness of stroke prevention in
AF from all published randomized trials of antithrombotic
therapy (41). Sixteen trials involving approximately 10,000
participants were analyzed (mean follow-up, 1.7 years). The
superiority of adjusted-dose warfarin over aspirin was un-
equivocal. When warfarin and aspirin were individually
compared with placebo, the occurrence of stroke was de-
creased by 60% and 20%, respectively. Although warfarin
confers a relative risk reduction of 40% to 50% in all patients
with stroke compared with aspirin, the magnitude of benefit
is directly proportional to an increase in the inherent risk of
stroke. This finding has important clinical implications.
Because the concern for bleeding complications is under-
standably greater among the elderly high-risk subgroup,
these patients are also at higher risk for stroke and may be
less likely to receive warfarin (42,43). In this respect, risk
stratification on the basis of the SPAF-III criteria might
identify subgroups of older patients who can be treated with
aspirin alone, particularly in the absence of a history of
hypertension (37). In addition to its proven effectiveness for
stroke prevention, warfarin therapy may have an impact on
multi-infarct dementia and so may also benefit cognitive
function in the elderly; however, this effect is purely spec-
ulative (43,44). Eventually, anticoagulation in the elderly
may be facilitated by tight control of the International
Normalized Ratio with simpler methods, such as finger-
stick collection as opposed to venous blood samples (43,45).
From the randomized trials of nonrheumatic AF (5,46),
the overall risk of hemorrhage attributable to this arrhyth-
mia was low. Established risk factors for intracranial hem-
orrhage in anticoagulated patients include age, uncontrolled
hypertension and anticoagulation level above target range.
LONE AF
By definition, lone AF occurs in the absence of structural
heart disease, as determined by the physical examination,
Figure 3. Pathophysiologic mechanisms and associations between atrial fibrillation and stroke. EF 5 ejection fraction; LA 5 left atrium; LV 5 left
ventricle. (From Gersh [3]; by permission of Futura Publishing Company. Original figure, courtesy of J. H. Chesebro, MD).
Table 1. Risk Factors for Stroke in Atrial Fibrillation
Meta-analysis of Prior
Large Trials (36) SPAF-III (37)
Prior stroke, transient ischemic
attack
Prior thromboembolism
Systolic BP , 160 mm Hg
History of hypertension Female, age . 75 years
Increasing age (by decade)
History of diabetes
History of CHF
Recent CHF, fractional
shortening ,25%
BP 5 blood pressure; CHF 5 congestive heart failure; SPAF-III 5 Stroke
Prevention in Atrial Fibrillation trial.
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electrocardiography, chest radiography and echocardiogra-
phy. The prevalence of lone AF depends on the age of the
population under consideration and whether AF is parox-
ysmal or chronic; it ranges from 2% to 31% (47–49).
Stroke risk in lone AF. The risk of stroke in subjects with
lone AF is governed largely by the presence and extent of
additional risk factors (Fig. 4, Table 1). In an early study of
the Framingham population (47), an approximately fourfold
risk of stroke was demonstrated in subjects with lone AF
compared with an age- and gender-matched population.
These patients had one or more risk factors for stroke; 56%
were older than 70 years, and 32% had a history of
hypertension. A subsequent study from Olmsted County,
Minnesota (48), included subjects with no risk factors,
limited to patients younger than 60 years. During a mean
follow-up of approximately 17 years, the risk of stroke was
very low (0.55/100 patient-years). The most recent experi-
ence from the Olmsted County population is in lone AF
with one risk factor (i.e., age older than 60 years) (50). The
combined risk of stroke and transient ischemic attack was
intermediate, being increased compared with that in con-
trols but substantially less than that described for the
original Framingham population (47). Another difference
between younger and older patients lies in the proportion in
which chronic AF has developed at follow-up (Fig. 5).
Chronicity of AF and stroke risk. In a recent study of
patients younger than 50 years from Trieste, Italy, most
patients (66%) remained in paroxysmal AF during a 10-year
follow-up (49). This group experienced a low thromboem-
bolism rate of 0.36/100 patient-years. In contrast, the 34%
of patients with chronic AF had a significantly higher rate of
thromboembolism, 1.3/100 patient-years, suggesting that in
addition to age, chronicity may be a risk factor for stroke in
the lone AF population. In the Olmsted County study (48),
the risk of thromboembolism was not significantly different
in the young (,60 years) patients with chronic AF, who
made up 22% of the population at the end of follow-up
(0.51 vs. 0.55/100 patient-years overall). An explanation for
chronicity as a risk factor may be provided by the echocar-
diographic documentation of increased left atrial dimen-
sions in patients with chronic versus paroxysmal AF. An
increased left atrial dimension previously has been shown to
be a risk factor for stroke (51). Although patients younger
than 50 years who have chronic AF are the minority, the
decision to use anticoagulation in this group may be
justified. The impact of warfarin on lifestyle, occupational
hazard and patient compliance is critical to the judicious
tailoring of therapy to the individual patient (52).
AF AND LV DYSFUNCTION
Atrial fibrillation coexists with LV dysfunction in a signif-
icant proportion of the population with congestive heart
failure (CHF). Atrial fibrillation is diagnosed in 10% to 35%
of patients with CHF during the course of the disease and
is related to the clinical severity of its symptoms
(14,18,21,23,53,54). Congestive heart failure was a power-
ful independent predictor of the occurrence of AF in the
Framingham study, in both symptomatic and asymptomatic
LV dysfunction (55).
AF: cause as well as effect of LV dysfunction. In most
patients with CHF, AF is attributed to the pathophysio-
logic mechanism of stretch-mediated arrhythmogenesis,
with larger left atrial volumes in those patients with AF than
in those with AF in the absence of LV dysfunction (56,57).
In at least a subset of the population with CHF, AF is a
precursor, and the etiologic mechanism, of LV dysfunction.
The entity of AF-induced cardiomyopathy, first described
more than 50 years ago, is currently experiencing a resur-
gence of interest (58,59).
Tachycardia-induced cardiomyopathy. Clinically, pa-
tients with this syndrome may present with marked LV
dysfunction, which is often disproportionate to the severity
of symptoms, but the importance is that ejection fraction
and LV dimensions may revert to normal after the estab-
lishment of sinus rhythm or effective rate control. The
frequency of this entity is not established, but in a series of
106 patients undergoing atrioventricular nodal ablation and
Figure 4. Analysis of thromboembolic risk in three studies of patients with
lone atrial fibrillation according to the number of risk factors for stroke and
age. (From Gersh BJ, Antithrombotic therapy in nonrheumatic/
nonvalvular atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:461–71.
By permission of Futura Publishing Company). Figure 5. Type of atrial fibrillation (Afib) at diagnosis and at last follow-up
in Olmsted County patients age 60 years or younger and those older than
60 years. Among younger patients, 20% never had a recurrence, 58% had
recurrent disease, and only 22% had chronic atrial fibrillation at follow-up.
Among older patients, 67% were in chronic Afib at follow-up. (Data from
Kopecky et al. [48,50]).
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permanent pacemaker implantation, LV dysfunction was
noted before ablation in 45%. Three months after ablation,
there was an approximately 30% improvement in ejection
fraction for the group as a whole, but a dramatic improve-
ment (ejection fraction 30% to approximately 60%) was
noted in approximately 20% of patients (60). These data
suggest that a heightened suspicion for a diagnosis of
AF-induced cardiomyopathy should be maintained. Given
its potential for reversibility, its relative infrequency belies
its importance.
Detrimental effects in heart failure. In patients with
“preexisting” LV dysfunction, the detrimental role of AF on
LV function and clinical CHF is probably much more
common than initially suspected. In the Studies Of Left
Ventricular Dysfunction (SOLVD) trials of symptomatic
and asymptomatic patients with LV dysfunction, the pres-
ence of AF at baseline was a powerful independent predictor
of death due to pump failure and rehospitalization for CHF.
Almost identical rates of sudden cardiac death for patients
with AF and those with sinus rhythm provide highly
suggestive evidence that AF is the cause and not just a
“marker” of more severe LV dysfunction and CHF. If AF
were solely a “marker,” one would have expected sudden
death rates to be increased in addition to mortality associ-
ated with pump failure. Moreover, in a series of patients
with stable CHF, the development of paroxysmal AF and a
reduction in the contribution of the left atrium to LV filling
predicted the subsequent development of AF. This, in turn,
was followed by clinical and hemodynamic deterioration
and a worse prognosis (61).
Mechanisms of increased mortality. The mechanisms
whereby AF adversely affects mortality may be multifacto-
rial. The presence of an irregular ventricular rhythm has
adverse hemodynamic consequences, which may have an
impact on pump failure in the long term (62). Well-
described repolarization abnormalities in CHF are known
to increase the risk of fatal arrhythmogenesis in both
humans and animal models (63,64). In addition, the in-
creased propensity for proarrhythmia in subjects with CHF
has been documented in several large series (65,66), which
may be related to significant modulation of antiarrhythmic
drug effects in heart failure (67,68).
Clinical implications of two epidemics (AF and CHF).
Clearly, therefore, the importance of the association of AF
and LV dysfunction extends well beyond the unusual, but
eminently curable, entity of tachycardia-induced cardiomy-
opathy. Atrial fibrillation and heart failure represent the
intersection of two common diseases, both of which have
been labeled “new epidemics” (2,69). The clinical manage-
ment is complex, but natural history studies suggest that the
maintenance of sinus rhythm and, at the very least, metic-
ulous rate control of the ventricular response during AF are
key components of the therapeutic strategy in patients with
CHF. Rate control cannot be assessed solely at rest, and it
is relevant that in the SOLVD database the adverse impact
of AF on subsequent mortality was independent of resting
heart rates (53). Adequate rate control, therefore, is defined
as a heart rate of 60 to 90 beats/min on a 24-h ambulatory
monitor or as an appropriate increase in response to exercise
(70).
Lack of improvement in ejection fraction may be related
to relatively high ejection fractions at baseline. The Ablate
and Pace trial studied a similar cohort of patients but
without a control group. In patients with decreased LV
function at baseline (mean ejection fraction, 31%), ejection
fraction increased to 41% at three months of follow-up, and
the improvement was sustained at one year (60). Thus,
although AF-induced cardiomyopathy is probably rare,
worsening of LV dysfunction by AF may be a relatively
common indication for intervention, either pharmacologic
or electrical.
ELECTRICAL AND STRUCTURAL REMODELING IN AF
Until recently, factors responsible for the maintenance of
AF in prone subjects were poorly understood. A significant
amount of information is now available regarding the role of
electrical and anatomical changes in the atria, which result
in the perpetuation of AF. Wijffels et al. (71) studied lone
AF in a goat model and demonstrated that once initiated,
AF tends to promote itself. It is likely that “AF begets more
AF” by the process of electrophysiologic remodeling, prob-
ably related to remodeling at the ion channel level (72,73).
What requires further clarification is the extent to which
these changes alter the clinical picture and the natural
history in patients with AF. The implications for prevention
of remodeling with early cardioversion are self-evident and
could provide a strong theoretical basis for therapeutic
strategies such as the implantable atrial defibrillator, trans-
esophageal echocardiographically guided cardioversion, pre-
ventive atrial pacing methods and the use of medications to
foster reverse remodeling.
FAMILIAL AF (THE GENETIC
RISK FACTOR: HYPOTHESIS FOR LONE AF)
As we enter the era of functional genomics, it is relevant to
consider the entity of “familial” AF. Several families with
AF have been documented (74,75), but it appears that
occurrence in the general population is uncommon. None-
theless, its frequency belies its importance as a key to our
understanding of factors that initiate AF. The identification
by Brugada et al. (76) of a chromosome mutation in subjects
with familial AF has uncovered exciting possibilities, but a
culprit gene or genes have not yet been identified. Hence,
continued investigation of families with hereditary AF and
genotyping to identify mutations intrinsically related to a
normal versus abnormal substrate is important. In regard to
the functional genomics of AF, we are still in the infancy
stage, but the potential is exciting.
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WHO SHOULD MAKE CLINICAL
DECISIONS FOR PATIENTS WITH AF?
With a condition as ubiquitous as AF, one of a variety of
physicians including cardiologists, internists, neurologists,
geriatricians or arrhythmia experts may be the first to come
in contact with the patient. Prerequisites for management of
such patients on an outpatient basis include knowledge of
agents that control heart rate, antiarrhythmic drugs, anti-
coagulants and electrical cardioversion. Interventions such
as device implantation and atrioventricular junction ablation
require an arrhythmia expert and a hospital-based special-
ized facility. The increasing incidence of AF may necessitate
the establishment of special AF clinics staffed by individuals
equipped with the requisite knowledge and facilities. In the
near future, anticoagulation follow-up will be simplified by
the use of patient-based testing.
CENTRAL ROLE OF EPIDEMIOLOGY
AND NATURAL HISTORY IN
CLINICAL DECISION MAKING: CONCLUSIONS
Currently, the epidemiology and natural history of AF
govern all aspects of the clinical management of the disease.
We are in the midst of an epidemic of AF, which is not
entirely explained on the basis of an aging population. Age
and the existence or development of concomitant heart
disease determines the decision to use anticoagulation for
stroke prophylaxis. Accordingly, warfarin is recommended
for patients older than 65 years or in the presence of heart
disease. A case has been made for aspirin alone in patients
younger than 75 years without other risk factors for stroke
such as hypertension or fractional shortening ,28% (77).
Recent data also suggest that the small subset of young
patients (,50 years) with chronic lone AF has a stroke risk
high enough to necessitate institution of warfarin therapy.
Young patients with paroxysmal lone AF still enjoy a very
low risk of stroke with no effect on mortality and do not
require anticoagulation. For unknown reasons, AF is an
independent predictor of hemorrhage, the occurrence of
which is associated with increasing age and stroke. Of
necessity, this translates into stringent control of anticoag-
ulation, especially in these subgroups.
Chronic AF and uncontrolled ventricular rate can both
result in LV dysfunction or contribute to its progression. In
either case, it may worsen mortality in patients with CHF,
the incidence and prevalence of which are continually
increasing. Radiofrequency ablation of the atrioventricular
junction with pacemaker implantation can improve symp-
toms and LV function in some patients, but the potential
for decrease in mortality needs to be proved. The critical
issue of rate versus rhythm control awaits completion of the
AF Follow-up Investigation of Rhythm Management trial,
which plans to enroll 5,300 patients, but results may not be
available for several years (78). Finally, the syndrome of AF
is an independent predictor of all-cause mortality, irrespec-
tive of age or cardiac or other comorbid conditions, for
reasons that remain poorly understood.
Recent developments, by affecting the natural history of
the disease, could eventually alter the nature of decision
making in patients with AF. The processes of electrical and
structural remodeling that perpetuate AF are reversible.
Trials of reverse remodeling of atrial structure and electro-
physiology with drugs such as beta-adrenergic blocking
agents are awaited. If sinus rhythm can be achieved, it
appears to beget sinus rhythm. The molecular basis of
familial AF is in the process of being defined. There is likely
a spectrum of molecular defects that predispose to familial
AF. The eventual goal is identification of the specific
functions of the mutant genes, which, in turn, promises a
range of new and specific therapeutic targets in the future.
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